3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal

This week got off to a rousing start for the biopharmaceutical world with Pfizer's (NYSE:PFE) announcement that it's acquiring Array BioPharma (NASDAQ:ARRY) for $11.4 billion. Anytime there's a sizable deal like this, it raises one question in the minds of investors: Who's next?

Addressing which big drugmakers might follow in Pfizer's footsteps by making an acquisition is easier than identifying the smaller companies that are the top buyout targets.